Bedke, J. Et Al. 2024. Nivolumab (NIVO) plus gemcitabine-cisplatin (GC) vs GC alone for previously untreated unresectable or metastatic urothelial carcinoma (mUC): results from the phase 3 CheckMate 901 trial. ONCOLOGY RESEARCH AND TREATMENT , 230.

Bedke, J., van der Heijden, M. S., Sonpavde, G., Powles, T., Necchi, A., Burotto, M., ... Schenker, M.(2024). Nivolumab (NIVO) plus gemcitabine-cisplatin (GC) vs GC alone for previously untreated unresectable or metastatic urothelial carcinoma (mUC): results from the phase 3 CheckMate 901 trial. ONCOLOGY RESEARCH AND TREATMENT , 230.

Bedke, Jens Et Al. "Nivolumab (NIVO) plus gemcitabine-cisplatin (GC) vs GC alone for previously untreated unresectable or metastatic urothelial carcinoma (mUC): results from the phase 3 CheckMate 901 trial," ONCOLOGY RESEARCH AND TREATMENT , 230, 2024

Bedke, Jens Et Al. "Nivolumab (NIVO) plus gemcitabine-cisplatin (GC) vs GC alone for previously untreated unresectable or metastatic urothelial carcinoma (mUC): results from the phase 3 CheckMate 901 trial." ONCOLOGY RESEARCH AND TREATMENT , pp.230, 2024

Bedke, J. Et Al. (2024) . "Nivolumab (NIVO) plus gemcitabine-cisplatin (GC) vs GC alone for previously untreated unresectable or metastatic urothelial carcinoma (mUC): results from the phase 3 CheckMate 901 trial." ONCOLOGY RESEARCH AND TREATMENT , p.230.

@article{article, author={Jens Bedke Et Al. }, title={Nivolumab (NIVO) plus gemcitabine-cisplatin (GC) vs GC alone for previously untreated unresectable or metastatic urothelial carcinoma (mUC): results from the phase 3 CheckMate 901 trial}, journal={ONCOLOGY RESEARCH AND TREATMENT}, year=2024, pages={230} }